Serina Therapeutics Net Worth
Serina Therapeutics Net Worth Breakdown | SER |
Serina Therapeutics Net Worth Analysis
Serina Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Serina Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Serina Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Serina Therapeutics' net worth analysis. One common approach is to calculate Serina Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Serina Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Serina Therapeutics' net worth. This approach calculates the present value of Serina Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Serina Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Serina Therapeutics' net worth. This involves comparing Serina Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Serina Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Serina Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Serina Therapeutics' net worth research are outlined below:
| Serina Therapeutics generated a negative expected return over the last 90 days | |
| Serina Therapeutics has high historical volatility and very poor performance | |
| Serina Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Serina Therapeutics was previously known as AgeX Therapeutics and was traded on NYSE MKT Exchange under the symbol AGE. | |
| The company reported the last year's revenue of 142 K. Reported Net Loss for the year was (14.8 M) with profit before taxes, overhead, and interest of 0. | |
| Serina Therapeutics generates negative cash flow from operations | |
| Serina Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 58.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from nypost.com: Jennifer Lopez interviewer awkwardly calls out her age Did he just say that |
Follow Serina Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 57.2 M.Market Cap |
|
Project Serina Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.30) | (1.37) | |
| Return On Capital Employed | (1.65) | (1.56) | |
| Return On Assets | (1.24) | (1.30) | |
| Return On Equity | (2.71) | (2.57) |
When accessing Serina Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Serina Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Serina Therapeutics' profitability and make more informed investment decisions.
Evaluate Serina Therapeutics' management efficiency
Serina Therapeutics has Return on Asset of (0.4529) % which means that on every $100 spent on assets, it lost $0.4529. This is way below average. Serina Therapeutics' management efficiency ratios could be used to measure how well Serina Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/18/2024, Return On Tangible Assets is likely to drop to -1.37. In addition to that, Return On Capital Employed is likely to grow to -1.56. At this time, Serina Therapeutics' Total Assets are relatively stable compared to the past year. As of 12/18/2024, Non Current Assets Total is likely to grow to about 11.8 M, while Return On Tangible Assets are likely to drop (1.37).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.97 | 5.21 | |
| Tangible Book Value Per Share | 4.40 | 4.62 | |
| Enterprise Value Over EBITDA | (1.93) | (2.02) | |
| Price Book Value Ratio | 2.71 | 2.58 | |
| Enterprise Value Multiple | (1.93) | (2.02) | |
| Price Fair Value | 2.71 | 2.58 | |
| Enterprise Value | 25.9 M | 24.6 M |
Serina Therapeutics benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Revenue 3.2 M | Quarterly Revenue Growth 6.286 | Revenue Per Share 0.787 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Serina Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Serina Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Serina Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Serina Therapeutics time-series forecasting models is one of many Serina Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Serina Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Serina Therapeutics Earnings per Share Projection vs Actual
Serina Therapeutics Corporate Executives
Elected by the shareholders, the Serina Therapeutics' board of directors comprises two types of representatives: Serina Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Serina. The board's role is to monitor Serina Therapeutics' management team and ensure that shareholders' interests are well served. Serina Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Serina Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Bentley | Chief CoFounder | Profile | |
| Milton Harris | CoFounder Board | Profile |
Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.